Phathom Pharmaceuticals, Inc.
NASDAQ:PHATBiotechnology
-$0.27 today
- Market cap
- $430.84M
- Beta
- 0.51
- P/E (TTM)
- -5.6
- EPS (TTM)
- -$1.92
Volume 1.67M
Average 1.21M
PHAT Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Phathom Pharmaceuticals, Inc.NASDAQ: PHAT
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development declines year over year
Q1 FY2026 research & development of $7.77M fell 15.4% year over year, behind the -7.3% change in trailing-twelve-month research & development. Sequentially, it rose 3.7% from the prior quarter. Over 3 fiscal years it compounded at -22.9% a year.
Context
- Research & development amounted to 18.7% of revenue in FY2025, down 43.0 pp from a year earlier.
- Research & development increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -15.4% toward the trailing-twelve-month pace of -7.3%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 32.78M USD
- Year-over-year change
- -3.8%
- 4-year CAGR
- -18.0%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 32.78M | -3.8% |
| FY2024 | 2024-12-31 | 34.08M | -31.7% |
| FY2023 | 2023-12-31 | 49.9M | -30.2% |
| FY2022 | 2022-12-31 | 71.44M | -1.2% |
| FY2021 | 2021-12-31 | 72.34M | — |
Research & Development vs competitors
How PHAT compares with its peers on the latest reported figures
- PHAT's LTM Mar 2026 research & development of $31.37M is the lowest of the 2 companies compared; the peer median is $74.32M.
- Its year-over-year change of -7.3% is the lowest of 2, against a peer median of +33.9%.
- Research & development amounts to 15.3% of revenue for PHAT, versus a peer median of 17.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $74.32M | +33.9% | +24.8% | 17.4% | |
| LTM Mar 2026 | $31.37M | -7.3% | -22.9% | 15.3% | |
| Peer median (excluding PHAT) | $74.32M | +33.9% | +24.8% | 17.4% | |
Competitors are the stored peer set for PHAT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 682K | 55.25M | 175.11M |
| Cost of Revenue | 521K | 620K | 167K | 7.97M | 22.6M |
| Gross Profit | (521K) | (620K) | 515K | 47.28M | 152.51M |
| Gross Margin | — | — | 75.5% | 85.6% | 87.1% |
| Research & Development | 72.34M | 71.44M | 49.9M | 34.08M | 32.78M |
| Selling, General & Admin | 62.22M | 100.38M | 117.93M | 290.66M | 279.72M |
| Operating Expenses | 134.56M | 171.82M | 167.83M | 324.75M | 312.5M |
| Depreciation & Amortization | 521K | 620K | 575K | 795K | 633K |
| EBITDA | (136.57M) | (169.8M) | (159.05M) | (261.52M) | (152.5M) |
| EBITDA Margin | — | — | -23321.0% | -473.3% | -87.1% |
| Operating Income | (135.08M) | (172.44M) | (167.31M) | (277.47M) | (159.99M) |
| Operating Margin | — | — | -24532.6% | -502.2% | -91.4% |
| Interest Income | 41K | 2.13M | 7.88M | 15.16M | 7.04M |
| Interest Expense | 6.79M | 27.31M | 41.97M | 72.01M | 68.12M |
| Other Income / Expenses | (8.8M) | (25.28M) | (34.28M) | (56.86M) | (61.26M) |
| Income Before Tax | (143.88M) | (197.72M) | (201.59M) | (334.33M) | (221.25M) |
| Pre-Tax Margin | — | — | -29558.9% | -605.1% | -126.3% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (143.88M) | (197.72M) | (201.59M) | (334.33M) | (221.25M) |
| Net Margin | — | — | -29558.9% | -605.1% | -126.3% |
| EPS (Basic) | (4.00) | (5.70) | (3.93) | (5.29) | (3.03) |
| EPS (Diluted) | (4.00) | (5.70) | (3.93) | (5.29) | (3.03) |
| Weighted Avg Shares | 37M | 39.12M | 51.29M | 63.18M | 72.92M |
| Weighted Avg Shares (Diluted) | 37M | 39.12M | 51.29M | 63.18M | 72.92M |
Phathom Pharmaceuticals, Inc.
NASDAQ:PHAT
Intrinsic Alpha fair value
Locked
Current Price
$5.30
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.